Speakers:
-
Muriel Pate, Medication Safety Specialist Pharmacist, HSE Quality & Patient Safety Directorate
-
Marie Philbin, Chief I Antimicrobial Pharmacist, National Antimicrobial Resistance & Infection Control Team, HSE
Summary:
In this webinar, the speaker discusses the use of Paxlovid for the treatment of COVID-19. They highlight that Paxlovid is indicated for adults with COVID-19 who do not require supplemental oxygen and are at increased risk of severe illness. The drug is a combination of two drugs, neurmatrelvar and rotonovir, and has received conditional approval from the European Medicines Agency based on the results of the EPIC-HR study. They emphasises that Paxlovid is not a substitute for vaccination and that vaccines are considered superior to current treatments. They also discuss the eligibility criteria, dosing information, adverse effects, and drug interactions associated with Paxlovid. Overall, careful consideration of medication history and safety precautions is crucial when prescribing and dispensing Paxlovid for the treatment of COVID-19.
Due to the rapid pace of change in COVID-19 therapeutics please consult the most up-to-date versions of any algorithms, support resources or guidance referred to in this webinar